Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 1 Basket Trial of TGFBR2 KO CAR27/IL-15 NK Cells for R/R Lymphoid Malignancies
NCT07444632Phase 1Recruiting
- Sponsor
- University of Texas MD Anderson Cancer Center
- Start
- May 2026
- Primary completion
- Sep 2030
- Modality
- Gene Editing, Gene Silencing, Lymphokine-Activated Killer Cells
- Countries
- 1
01
Overview
Phase 1, open-label trial of TGFBR2 KO CAR.70/IL-15 NK cells in B-cell non-Hodgkin lymphoma, Hodgkin lymphoma (HL), T-cell non-Hodgkin lymphoma and 1 more (2 arms), sponsored by University of Texas MD Anderson Cancer Center. Primary endpoints: Safety and Adverse Events at 1 year, Recommended Phase 2 Dose and 1 more. Started May 2026; status: recruiting.
02
Drugs
TGFBR2 KO CAR.70/IL-15 NK cells
03
Conditions
B-cell non-Hodgkin lymphomaHodgkin lymphoma (HL)T-cell non-Hodgkin lymphomaB cell acute lymphoblastic leukemia (B-ALL)
Beyond the preview
Go deeper on NCT07444632.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07444632.